SSA
IONS icon

Schonfeld Strategic Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200,839
Closed -$13.1M – 2289
2025
Q3 		$13.1M Sell
200,839
-248,367
-55% -$12.1M 0.07% 277
2025
Q2 		$17.7M Sell
449,206
-111,153
-20% -$3.64M 0.12% 189
2025
Q1 		$16.9M Buy
560,359
+188,978
+51% +$6.19M 0.1% 194
2024
Q4 		$13M Buy
371,381
+8,493
+2% +$317K 0.08% 243
2024
Q3 		$14.5M Sell
362,888
-360,730
-50% -$16.8M 0.1% 216
2024
Q2 		$34.5M Buy
723,618
+552,758
+324% +$22.7M 0.22% 75
2024
Q1 		$7.41M Sell
170,860
-142,414
-45% -$6.79M 0.05% 487
2023
Q4 		$15.8M Buy
313,274
+251,726
+409% +$12.1M 0.11% 220
2023
Q3 		$2.79M Buy
61,548
+22,504
+58% +$928K 0.02% 715
2023
Q2 		$1.6M Sell
39,044
-3,165
-7% -$122K 0.01% 825
2023
Q1 		$1.51M Sell
42,209
-223,589
-84% -$8.4M 0.01% 782
2022
Q4 		$10M Buy
265,798
+58,126
+28% +$2.44M 0.08% 302
2022
Q3 		$9.19M Buy
207,672
+77,649
+60% +$3.27M 0.08% 338
2022
Q2 		$4.81M Buy
130,023
+74,480
+134% +$2.81M 0.05% 485
2022
Q1 		$2.06M Buy
+55,543
New +$1.82M 0.02% 726
2021
Q2 		– Sell
-21,101
Closed -$948K – 2112
2021
Q1 		$948K Buy
21,101
+5,966
+39% +$333K 0.01% 915
2020
Q4 		$855K Buy
+15,135
New +$754K 0.01% 864
2020
Q2 		– Sell
-12,436
Closed -$588K – 1378
2020
Q1 		$588K Buy
+12,436
New +$693K 0.04% 527
2017
Q2 		– Sell
-10,431
Closed -$419K – 686
2017
Q1 		$419K Sell
10,431
-9,569
-48% -$430K 0.04% 400
2016
Q4 		$957K Buy
+20,000
New +$791K 0.12% 237
2016
Q2 		– Sell
-8,731
Closed -$354K – 477
2016
Q1 		$354K Buy
+8,731
New +$355K 0.14% 191

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Schonfeld Strategic Advisors's IONS Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Ionis Pharmaceuticals (IONS) in Q4 2025, closing a stake of 200,839 shares — an estimated $13.1M sold.

Schonfeld Strategic Advisors first reported a position in IONS in Q1 2016 and held it in 21 quarters. The position peaked at $34.5M in Q2 2024. 491 funds tracked by Wall St. Rank hold IONS as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Ionis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 200,839 Ionis Pharmaceuticals shares in Q4 2025, an estimated $13.1M.
  • Schonfeld Strategic Advisors first reported a position in Ionis Pharmaceuticals in Q1 2016 and held it in 21 quarters.
  • Schonfeld Strategic Advisors's Ionis Pharmaceuticals position peaked at $34.5M in Q2 2024.
  • 491 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.